---
title: Screening for Bleeding Disorders in Children
nct_id: NCT05214300
overall_status: COMPLETED
sponsor: University Hospital, Montpellier
study_type: OBSERVATIONAL
primary_condition: Bleeding Disorder
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05214300.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05214300"
ct_last_update_post_date: 2022-01-28
last_seen_at: "2026-05-12T06:32:12.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Screening for Bleeding Disorders in Children

**Official Title:** Screening for Bleeding Disorders in Children: Evaluation of the Elements of the Interrogation, the Screening Workup and the Clinical Scores

**NCT ID:** [NCT05214300](https://clinicaltrials.gov/study/NCT05214300)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 96
- **Lead Sponsor:** University Hospital, Montpellier
- **Conditions:** Bleeding Disorder
- **Start Date:** 2019-12-01
- **Completion Date:** 2021-12-20
- **CT.gov Last Update:** 2022-01-28

## Brief Summary

The investigators try to improve the screening of bleeding disorders in children by identifying symptoms, laboratory abnormalities and clinical scores discriminating patients congenital bleeding disorders in order to create a simple screening algorithm applicable in pediatrics, aiming for use in pre-anesthetic consultation and in consultation by pediatricians and general practitioners.

## Detailed Description

Objective : To determine simple clinical and biological factors that can improve the screening of hemostatic diseases at risk of hemorrhage in children.

Method:

* Retrospective inclusion of all patients \<18 years referred to the CRTH in pediatric consultation for the reason of exploration of a hemorrhagic syndrome or exploration of an anomaly in the hemostasis assessment.
* Data collected (by collection in the medical file):

Patient data: Age, sex, personal and family history of hemorrhagic disease

Clinical data: hemorrhagic symptomatology (epistaxis, gingivorrhagia, etc.) Biological data: PT, TCK, factor assay, platelet function Medical data: complete diagnosis if diagnosis of hemorrhagic disease

* Scores: HEMOSTOP, PBQ, ISTH, TOSETTO score
* Analyzes: calculation of the Odd Ratio, AUC, Se, Sp, VPP, VPN for different clinical / biological factors and each score.

## Eligibility

- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* referred by their general practitioner or another caring physician for evaluation of bleeding symptoms
* abnormal laboratory test results or family study
* the patient being the first-degree relative of a patient with a known bleeding disorder.

Exclusion criteria:

\- older than 18 years old.
```

## Primary Outcomes

- **Observe the correlation between the data of the interrogation** _(time frame: 1 day)_ — Observe the correlation between the data of the interrogation, the clinical examination and the clinical history and the demonstration of a confirm congenital bleeding disorder.

## Locations (1)

- Uhmontpellier, Montpellier, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.uhmontpellier|montpellier||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05214300.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05214300*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*